Download Files:
Products Details
Product Description
– CCG-232601 (compound 8f) is a potent and orally active Rho/MRTF/SRF transcriptional pathway inhibitor. CCG-232601 inhibits the development of Bleomycin-induced dermal fibrosis in mice. CCG-232601 has the potential for the research of antifibrotic for systemic scleroderma[1].
Web ID
– HY-111432
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C24H20ClF2N3O2
References
– [1]Hutchings KM, et al. Pharmacokinetic optimitzation of CCG-203971: Novel inhibitors of the Rho/MRTF/SRF transcriptional pathway as potential antifibrotic therapeutics for systemic scleroderma. Bioorg Med Chem Lett. 2017 Apr 15;27(8):1744-1749.
CAS Number
– 1922099-21-5
Molecular Weight
– 455.88
SMILES
– O=C(C1CN(C(C2=CC=CC(C3=CC=NC=C3)=C2)=O)CC(F)(F)C1)NC4=CC=C(Cl)C=C4
Clinical Information
– No Development Reported
Research Area
– Others
Solubility
– 10 mM in DMSO
Target
– Ras
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
